The ongoing observational study at the University Medical Center Hamburg-Eppendorf aims to identify novel biomarkers for the non-invasive diagnosis of tuberculosis, addressing a significant unmet need in TB diagnostics, particularly for patients unable to produce sputum. The potential for a reliable, non-invasive diagnostic tool could enhance patient management and treatment outcomes, positioning the sponsor favorably in the diagnostic market for infectious diseases. The study's findings may lead to partnerships with diagnostic companies and could influence future product development strategies. Given the global burden of TB, successful outcomes could capture a substantial share of the diagnostics market, which is increasingly focused on rapid and accurate testing solutions.